Atopic Dermatitis
main-banner
Atopic Dermatitis
INNO-6052 Enrolling

Chronic Hand Eczema Study (40 Weeks)


Treatment: Oral Age: 18 Years


Who Can Participate?

Adults (18+) with chronic hand eczema (CHE) may participate.

 Inclusion Criteria

  • Moderate-to-severe CHE for 6 months or more
  • Have used a potent topical corticosteroid or systemic corticosteroid treatment in the past year that did not clear up or significantly reduce the CHE
  • If currently using an emollient on your hands, continue to do so at the same frequency for the study’s duration

 What Are The Benefits?

  • No cost to participate or receive treatment
  • Regular visits with study doctors who specialise in treating CHE (10 visits)
  • Will receive either an investigative oral treatment (study drug) or a placebo
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last?

  • 40 Weeks

Note: Participants 50 years old or older must have the shingles vaccination (or receive it within 6 weeks prior to starting trial participation).


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Irina Turchin

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 09, 2024

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

ClinicalTrials.gov ID

NCT06283550

Sponsor

Innovaderm Research Inc.

Study Description

  • Brief Summary:

    This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

  • Condition or Disease:

    Chronic Hand Eczema

  • Intervention/Treatment:

    Drug: Abrocitinib 200 mg
    Drug: Abrocitinib 100 mg
    Drug: Abrocitinib 200 mg
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and older (Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Adult subject, 18 years of age or older, at the time of consent.
Subject has a history of moderate to severe CHE for at least 6 months prior to Day 1.
Subject has refractory hand eczema
Subject has moderate to severe CHE at screening and Day 1, as defined by a hand PGA of 3 or 4.
Contraceptive use by women of childbearing potential or their male partners during the study and until ≥ 4 weeks after the last study product administration
Female subject of childbearing potential has had a negative serum pregnancy test at screening and negative urine pregnancy test on Day 1.
Subject is willing to participate and is capable of giving informed consent.
Subjects must be willing to comply with all study procedures and must be available for the duration of the study.

Exclusion Criteria:

Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
Subject has known or suspected allergic contact dermatitis of the hands and is unable to avoid exposure to the causative allergen or subjects with suspected or expected changes in irritant or allergen exposures from screening through the end of the study.
Subject has active skin infections of the hands.
Subject has a history or has current active psoriasis.
Subject has a history of eczema herpeticum within 12 months prior to screening, and/or a history of 2 or more episodes of eczema herpeticum in the past.
Subject has a history of skin disease or presence of skin condition.
Subject has a history of cancer prior to Day 1.
Subject has any clinically significant medical condition (including psychiatric condition) or physical/laboratory/vital signs abnormality.
Subject has a current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction.
Subject has a current or recent clinically significant viral, bacterial, fungal, or parasitic infection.
Subject has a history of clinically significant heart disease.
Subject is ≥ 50 years old AND has a history of heart attack, other clinically significant heart problems, stroke, or blood clots (in the opinion of the investigator).
Presence of laboratory abnormalities at the screening visit.
Subject has received any marketed or investigational biological agent within 12 weeks or 5 half lives (whichever is longer) prior to Day 1.
Subject has used any topical treatments that could have an impact on CHE within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, topical retinoids, crisaborole, calcineurin inhibitors, ruxolitinib, tars, bleach, bleach baths, antimicrobials, medical devices.
Subject has a known hypersensitivity to abrocitinib or its excipients.
Subject has a known history of clinically significant drug or alcohol abuse within 6 months prior to Day 1.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Atopic Dermatitis

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content